CIRCA TO RECEIVE 20% OF RPR DILACOR XR SALES IN 1995
CIRCA TO RECEIVE 20% OF RPR DILACOR XR SALES IN 1995, Circa Chairman Melvin Sharoky told analysts at the Bear Stearns Seventh Annual Health Care meeting in New York City Sept. 21. Circa, formerly Bolar, receives a 1% royalty on sales of the once-daily diltiazem product under an agreement with Rhone-Poulenc Rorer dating back to 1989, Sharoky said.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth